Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559255 | 0.90 | MAPT (0.73) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693643 | 0.88 | MAPT (0.67) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693641 | 0.88 | MAPT (0.75) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693638 | 0.87 | HTT (0.69) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693637 | 0.87 | HTT (0.69) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693634 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL16366745 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693650 | 0.85 | MAPT (0.63) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL15693649 | 0.83 | HPGD (0.64) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL8634298 | 0.83 | MAPT (0.61) | MAPTSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943506-B2 | BCL6 inhibitors as anticancer agents | CORNELL UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| WO-2014204859-A2 | BCL6 INHIBITORS AS ANTICANCER AGENTS | MELNICK ARI (US) | 2014-12-24 | — | — | WO | disclosed |
| US-8710082-B2 | Benzimidazole inhibition of biofilm formation | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710082-B2 | Benzimidazole inhibition of biofilm formation | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-0843671-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997003069-A1 | HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | MAPT 2263/4885SMN1; SMN2 4357/4885NPC1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.